<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00232934</url>
  </required_header>
  <id_info>
    <org_study_id>GISMM2001-A</org_study_id>
    <nct_id>NCT00232934</nct_id>
  </id_info>
  <brief_title>Melphalan, Prednisone and Thalidomide Versus Melphalan and Prednisone in Elderly Myeloma Patients</brief_title>
  <official_title>Phase III, Prospective, Open Label, Multicenter, Randomized Trial of Melphalan, Prednisone and Thalidomide Versus Melphalan and Prednisone as First Line Therapy in Myeloma Patients Aged &gt;65.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gruppo Italiano per lo Studio del Mieloma Multiplo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gruppo Italiano per lo Studio del Mieloma Multiplo</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the association of Thalidomide to Melphalan
      and Prednisone is effective in the treatment of newly diagnosed elderly multiple myeloma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intermittent courses of Melphalan and Prednisone (MP) have been the first line therapy in
      multiple myeloma, for many years.

      Advances in systemic and supportive therapy increased remission rates and overall survival,
      but multiple myeloma still remains an incurable haematological malignancy. Several
      preliminary studies demonstrate the efficacy of thalidomide in refractory and relapsed
      multiple myeloma with an overall response rate of 30 to 60%.

      Due to its activity, Thalidomide will be evaluated in association with MP in a randomized
      study for newly diagnosed myeloma patients not eligible for high-dose chemotherapy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2002</start_date>
  <completion_date>May 2010</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response Rate</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Event Free Survival</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
  </secondary_outcome>
  <enrollment>400</enrollment>
  <condition>Multiple Myeloma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thalidomide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  untreated myeloma patients

          -  age &gt;65 years of age or younger but excluded from transplant procedure

          -  Durie &amp; Salmon stage II or III myeloma and measurable disease.

          -  Patients agreed to use contraception

        Exclusion Criteria:

          -  other cancer

          -  psychiatric disease and any grade 2 peripheral neuropathy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mario Boccadoro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Divisione di Ematologia dell'Università di Torino, Azienda Ospedaliera S.Giovanni Battista, Torino, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antonio Palumbo, MD</last_name>
    <role>Study Director</role>
    <affiliation>Divisione di Ematologia dell'Università degli Studi di Torino, Azienda Ospedaliera S.Giovanni Battista, Torino, Italy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Divisionedi Ematologia - Ospedali Riuniti</name>
      <address>
        <city>Bergamo</city>
        <zip>24127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto di Ematologia e Oncologia Medica &quot;Seragnoli&quot;- Università di Bologna</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia - Az. Osp. S.Croce Carle</name>
      <address>
        <city>Cuneo</city>
        <zip>26100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O. di Ematologia e Trapianto di Cellule Staminali, IRCCS Casa Sollievo della Sofferenza</name>
      <address>
        <city>Foggia</city>
        <zip>71013</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ematologia - H.S. Gerardo</name>
      <address>
        <city>Monza</city>
        <zip>20052</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cattedra e Divisione di Ematologia Università Federico II</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia e Trapianto di Midollo Osseo- Ospedale Cervello</name>
      <address>
        <city>Palermo</city>
        <zip>90146</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Medica I, Policlinico Monteluce</name>
      <address>
        <city>Perugia</city>
        <zip>06123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia Ospedali Riuniti</name>
      <address>
        <city>Reggio Calabria</city>
        <zip>89100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cattedra e Divisione di Ematologia Università TOR Vergata Ospedale S.Eugenio</name>
      <address>
        <city>Roma</city>
        <zip>00100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Biotecnologie ed Ematologia - Università La Sapienza</name>
      <address>
        <city>Roma</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto di Ematologia - Università Cattolica</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia dell'Università di Torino, Azienda Ospedaliera S.Giovanni Battista</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>San Miguel JF, Bladé Creixenti J, García-Sanz R. Treatment of multiple myeloma. Haematologica. 1999 Jan;84(1):36-58. Review.</citation>
    <PMID>10091392</PMID>
  </reference>
  <reference>
    <citation>Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, Munshi N, Anaissie E, Wilson C, Dhodapkar M, Zeddis J, Barlogie B. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999 Nov 18;341(21):1565-71. Erratum in: N Engl J Med 2000 Feb 3;342(5):364.</citation>
    <PMID>10564685</PMID>
  </reference>
  <reference>
    <citation>Hideshima T, Chauhan D, Shima Y, Raje N, Davies FE, Tai YT, Treon SP, Lin B, Schlossman RL, Richardson P, Muller G, Stirling DI, Anderson KC. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood. 2000 Nov 1;96(9):2943-50.</citation>
    <PMID>11049970</PMID>
  </reference>
  <verification_date>October 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 4, 2005</study_first_submitted>
  <study_first_submitted_qc>October 4, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 5, 2005</study_first_posted>
  <last_update_submitted>October 4, 2005</last_update_submitted>
  <last_update_submitted_qc>October 4, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 5, 2005</last_update_posted>
  <keyword>Myeloma</keyword>
  <keyword>Thalidomide</keyword>
  <keyword>Diagnosis</keyword>
  <keyword>Elderly patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

